China Oncology ›› 2022, Vol. 32 ›› Issue (9): 765-771.doi: 10.19401/j.cnki.1007-3639.2022.09.002
• Specialists' Commentary • Previous Articles Next Articles
Received:
2022-08-02
Revised:
2022-09-03
Online:
2022-09-30
Published:
2022-10-24
Contact:
WU Wenming
CLC Number:
WANG Xianze, WU Wenming. Evolution in the surgical treatment concepts of pancreatic neuroendocrine tumors[J]. China Oncology, 2022, 32(9): 765-771.
[1] |
FAN J H, ZHANG Y Q, SHI S S, et al. A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in China[J]. Oncotarget, 2017, 8(42): 71699-71708.
doi: 10.18632/oncotarget.17599 |
[2] | WU W M, CHEN J, BAI C M, et al. The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020)[J]. Chin J Surg, 2021, 59(6): 401-421. |
[3] |
CIVES M, STROSBERG J R. Gastroenteropancreatic neuroendocrine tumors[J]. CA Cancer J Clin, 2018, 68(6): 471-487.
doi: 10.3322/caac.21493 |
[4] |
DASARI A, SHEN C, HALPERIN D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States[J]. JAMA Oncol, 2017, 3(10): 1335-1342.
doi: 10.1001/jamaoncol.2017.0589 pmid: 28448665 |
[5] |
SCARPA A, CHANG D K, NONES K, et al. Whole-genome landscape of pancreatic neuroendocrine tumours[J]. Nature, 2017, 543(7643): 65-71.
doi: 10.1038/nature21063 |
[6] | 刘大为. 一个值得深思的问题:重症治疗是病情导向抑或治疗目标导向[J]. 中华内科杂志, 2022, 61(6): 607-610. |
LIU D W. Target directed therapy in critical patients, to be or not to be[J]. Chin J Intern Med, 2022, 61(6): 607-610. | |
[7] | 中国抗癌协会神经内分泌肿瘤专业委员会. 中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)[J]. 中国癌症杂志, 2022, 32(6): 545-579. |
Society of Neuroendocrine Neoplasm of China Anti-Cancer Association. China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasm (2022 edition)[J]. CHINA ONCOLOGY, 2022, 32(6): 545-579.
doi: 10.19401/j.cnki.1007-3639.2022.06.010 |
|
[8] |
KULKARNI R, KABIR I, HODSON J, et al. Impact of the extent of resection of neuroendocrine tumor liver metastases on survival: a systematic review and meta-analysis[J]. Ann Hepatobiliary Pancreat Surg, 2022, 26(1): 31-39.
doi: 10.14701/ahbps.21-101 |
[9] |
MEROLA E, FALCONI M, RINKE A, et al. Radical intended surgery for highly selected stage Ⅳ neuroendocrine neoplasms G3[J]. Am J Surg, 2020, 220(2): 284-289.
doi: 10.1016/j.amjsurg.2020.03.009 |
[10] |
MEROLA E, RINKE A, PARTELLI S, et al. Surgery with radical intent: is there an indication for G3 neuroendocrine neoplasms?[J]. Ann Surg Oncol, 2020, 27(5): 1348-1355.
doi: 10.1245/s10434-019-08049-5 pmid: 31720931 |
[11] |
LEWIS A, RAOOF M, ITUARTE P H G, et al. Resection of the primary gastrointestinal neuroendocrine tumor improves survival with or without liver treatment[J]. Ann Surg, 2019, 270(6): 1131-1137.
doi: 10.1097/SLA.0000000000002809 pmid: 29746336 |
[12] |
ZHANG X F, XUE F, DONG D H, et al. New nodal staging for primary pancreatic neuroendocrine tumors: a multi-institutional and national data analysis[J]. Ann Surg, 2021, 274(1): e28-e35.
doi: 10.1097/SLA.0000000000003478 |
[13] |
RINDI G, KLIMSTRA D S, ABEDI-ARDEKANI B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal[J]. Mod Pathol, 2018, 31(12): 1770-1786.
doi: 10.1038/s41379-018-0110-y |
[14] |
LUO G P, JAVED A, STROSBERG J R, et al. Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society systems[J]. J Clin Oncol, 2017, 35(3): 274-280.
doi: 10.1200/JCO.2016.67.8193 pmid: 27646952 |
[15] |
ZHANG X F, XUE F, WU Z, et al. Development and validation of a modified eighth AJCC staging system for primary pancreatic neuroendocrine tumors[J]. Ann Surg, 2022, 275(6): e773-e780.
doi: 10.1097/SLA.0000000000004039 |
[16] |
WANG M, DING D, QIN T T, et al. New staging classification for pancreatic neuroendocrine neoplasms combining TNM stage and WHO grade classification[[J]. Cancer Lett, 2021, 518: 207-213.
doi: 10.1016/j.canlet.2021.07.018 |
[17] | YAN J, YU S N, JIA C W, et al. Molecular subtyping in pancreatic neuroendocrine neoplasms: new insights into clinical, pathological unmet needs and challenges[J]. Biochim Biophys Acta Rev Cancer, 2020, 1874(1): 188367. |
[18] |
KAWASAKI K, TOSHIMITSU K, MATANO M, et al. An organoid biobank of neuroendocrine neoplasms enables genotype-phenotype mapping[J]. Cell, 2020, 183(5): 1420-1435.e21.
doi: 10.1016/j.cell.2020.10.023 pmid: 33159857 |
[19] |
SALLINEN V, HAGLUND C, SEPPÄNEN H. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: do size and symptoms matter?[J]. Surgery, 2015, 158(6): 1556-1563.
doi: 10.1016/j.surg.2015.04.035 |
[20] |
PAIK W H, LEE H S, LEE K J, et al. Malignant potential of small pancreatic neuroendocrine neoplasm and its risk factors: a multicenter nationwide study[J]. Pancreatology, 2021, 21(1): 208-214.
doi: 10.1016/j.pan.2020.11.016 pmid: 33281058 |
[21] |
MIRKIN K A, HOLLENBEAK C S, WONG J. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm[J]. J Surg Res, 2017, 211: 206-214.
doi: 10.1016/j.jss.2016.12.033 |
[22] |
HAN I W, PARK J, PARK E Y, et al. Fate of surgical patients with small nonfunctioning pancreatic neuroendocrine tumors: an international study using multi-institutional registries[J]. Cancers, 2022, 14(4): 1038.
doi: 10.3390/cancers14041038 |
[23] |
DE ROBERTIS R, MARIS B, CARDOBI N, et al. Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors?[J]. Eur Radiol, 2018, 28(6): 2582-2591.
doi: 10.1007/s00330-017-5236-7 pmid: 29352378 |
[24] |
PAIELLA S, LANDONI L, TEBALDI S, et al. Dual-tracer(68Ga-DOTATOC and 18F-FDG-)-PET/CT scan and G1-G2 nonfunctioning pancreatic neuroendocrine tumors: a single-center retrospective evaluation of 124 nonmetastatic resected cases[J]. Neuroendocrinology, 2022, 112(2): 143-152.
doi: 10.1159/000514809 |
[25] |
HACKENG W M, BROSENS L A A, KIM J Y, et al. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size[J]. Gut, 2022, 71(5): 961-973.
doi: 10.1136/gutjnl-2020-322595 |
[26] |
PEA A, YU J, MARCHIONNI L, et al. Genetic analysis of small well-differentiated pancreatic neuroendocrine tumors identifies subgroups with differing risks of liver metastases[J]. Ann Surg, 2020, 271(3): 566-573.
doi: 10.1097/SLA.0000000000003022 pmid: 30339629 |
[27] |
QUEVEDO R, SPREAFICO A, BRUCE J, et al. Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor[J]. Genome Med, 2020, 12(1): 38.
doi: 10.1186/s13073-020-00730-9 pmid: 32345369 |
[28] | TANG X, SHAO Y, YI X, et al. Metastatic timing and genetic heterogeneity in the evolution of a pancreatic neuroendocrine tumor[J]. Am J Gastroenterol, 2021, 116(4): 844-847. |
[29] |
RINDI G, METE O, UCCELLA S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms[J]. Endocr Pathol, 2022, 33(1): 115-154.
doi: 10.1007/s12022-022-09708-2 pmid: 35294740 |
[30] | TITAN A L, NORTON J A, FISHER A T, et al. Evaluation of outcomes following surgery for locally advanced pancreatic neuroendocrine tumors[J]. JAMA Netw Open, 2020, 3(11): e2024318. |
[31] | GAO S Z, SHI X H, MA H Y, et al. The effect of using long-acting octreotide as adjuvant therapy for patients with grade 2 pancreatic neuroendocrine tumors after radical resection[J]. J Pancreatol, 2020, 3(4): 167-172. |
[32] |
WANG W Q, ZHANG W H, GAO H L, et al. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors[J]. J Gastroenterol, 2021, 56(4): 395-405.
doi: 10.1007/s00535-021-01777-0 |
[33] |
PULVIRENTI A, JAVED A A, LANDONI L, et al. Multi-institutional development and external validation of a nomogram to predict recurrence after curative resection of pancreatic neuroendocrine tumors[J]. Ann Surg, 2021, 274(6): 1051-1057.
doi: 10.1097/SLA.0000000000003579 |
[34] |
CHAN C S, LADDHA S V, LEWIS P W, et al. ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup[J]. Nat Commun, 2018, 9(1): 4158.
doi: 10.1038/s41467-018-06498-2 pmid: 30315258 |
[35] |
LAWRENCE B, BLENKIRON C, PARKER K, et al. Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer[J]. NPJ Genom Med, 2018, 3: 18.
doi: 10.1038/s41525-018-0058-3 pmid: 30062048 |
[36] |
HONG X F, QIAO S T, LI F Q, et al. Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system[J]. Gut, 2020, 69(5): 877-887.
doi: 10.1136/gutjnl-2018-317233 pmid: 31462556 |
[37] |
SADANANDAM A, WULLSCHLEGER S, LYSSIOTIS C A, et al. A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics[J]. Cancer Discov, 2015, 5(12): 1296-1313.
doi: 10.1158/2159-8290.CD-15-0068 pmid: 26446169 |
[38] |
YAO J, GARG A, CHEN D, et al. Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials[J]. Endocr Relat Cancer, 2019, 26(4): 391-403.
doi: 10.1530/ERC-18-0332 |
[39] | WEI M Y, XU J, HUA J, et al. From the immune profile to the immunoscore: signatures for improving postsurgical prognostic prediction of pancreatic neuroendocrine tumors[J]. Front Immunol, 2021, 12: 654660. |
[40] |
KIDD M, MODLIN I, ÖBERG K. Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms[J]. Nat Rev Clin Oncol, 2016, 13(11): 691-705.
doi: 10.1038/nrclinonc.2016.85 pmid: 27273044 |
[41] |
YOUNG K, STARLING N, SADANANDAM A. The molecular biology of pancreatic neuroendocrine neoplasms: challenges and translational opportunities[J]. Semin Cancer Biol, 2020, 61: 132-138.
doi: S1044-579X(19)30291-3 pmid: 31577961 |
[42] |
GAY-CHEVALLIER S, DE MESTIER L, PERINEL J, et al. Management and prognosis of localized duodenal neuroendocrine neoplasms[J]. Neuroendocrinology, 2021, 111(8): 718-727.
doi: 10.1159/000508102 |
[43] |
WANG R, MOHAPATRA S, JOVANI M, et al. Risk factors for lymph node metastasis and survival of patients with nonampullary duodenal carcinoid tumors treated with endoscopic therapy versus surgical resection: analysis of the Surveillance, Epidemiology, and End Results program[J]. Gastrointest Endosc, 2021, 93(6): 1384-1392.
doi: 10.1016/j.gie.2020.12.012 pmid: 33347833 |
[44] |
RIMBAŞ M, HORUMBĂ M, RIZZATTI G, et al. Interventional endoscopic ultrasound for pancreatic neuroendocrine neoplasms[J]. Dig Endosc, 2020, 32(7): 1031-1041.
doi: 10.1111/den.13635 |
[45] |
MELITA G, PALLIO S, TORTORA A, et al. Diagnostic and interventional role of endoscopic ultrasonography for the management of pancreatic neuroendocrine neoplasms[J]. J Clin Med, 2021, 10(12): 2638.
doi: 10.3390/jcm10122638 |
[46] |
WANG M, PENG B, LIU J H, et al. Practice patterns and perioperative outcomes of laparoscopic pancreaticoduodenectomy in China: a retrospective multicenter analysis of 1029 patients[J]. Ann Surg, 2021, 273(1): 145-153.
doi: 10.1097/SLA.0000000000003190 |
[47] |
WANG M, LI D W, CHEN R F, et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(6): 438-447.
doi: 10.1016/S2468-1253(21)00054-6 |
[48] |
TAMBURRINO D, PARTELLI S, RENZI C, et al. Systematic review and meta-analysis on laparoscopic pancreatic resections for neuroendocrine neoplasms (PNENs)[J]. Expert Rev Gastroenterol Hepatol, 2017, 11(1): 65-73.
doi: 10.1080/17474124.2017.1253473 |
[49] |
ZHANG H, LAN X, PENG B, et al. Is total laparoscopic pancreaticoduodenectomy superior to open procedure? A meta-analysis[J]. World J Gastroenterol, 2019, 25(37): 5711-5731.
doi: 10.3748/wjg.v25.i37.5711 |
[50] | GIULIANI T, DE PASTENA M, PAIELLA S, et al. Pancreatic enucleation patients share the same quality of life as the general population at long-term follow-up: a propensity-score matched analysis[J]. Ann Surg, 2021. Online ahead of print. |
[51] | HUANG J, YADAV D K, XIONG C J, et al. Laparoscopic spleen-preserving distal pancreatectomy (LSPDP) versus open spleen-preserving distal pancreatectomy (OSPDP): a comparative study[J]. Can J Gastroenterol Hepatol, 2019, 2019: 9367868. |
[52] |
LI A Y, VISSER B C, DUA M M. Surgical indications and outcomes of resection for pancreatic neuroendocrine tumors with vascular involvement[J]. Cancers, 2022, 14(9): 2312.
doi: 10.3390/cancers14092312 |
[53] | WANG X Z, CHUNG W Y, CORREA E, et al. The integration of artificial intelligence models to augment imaging modalities in pancreatic cancer[J]. J Pancreatol, 2020, 3(4): 173-180. |
[54] |
BARI H, WADHWANI S, DASARI B V M. Role of artificial intelligence in hepatobiliary and pancreatic surgery[J]. World J Gastrointest Surg, 2021, 13(1): 7-18.
doi: 10.4240/wjgs.v13.i1.7 pmid: 33552391 |
[55] |
HERNANDEZ VARGAS S, KOSSATZ S, VOSS J, et al. Specific targeting of somatostatin receptor subtype-2 for fluorescence-guided surgery[J]. Clin Cancer Res, 2019, 25(14): 4332-4342.
doi: 10.1158/1078-0432.CCR-18-3312 pmid: 31015345 |
[56] |
LAUWERENDS L J, VAN DRIEL P B A A, BAATENBURG DE JONG R J, et al. Real-time fluorescence imaging in intraoperative decision making for cancer surgery[J]. Lancet Oncol, 2021, 22(5): e186-e195.
doi: 10.1016/S1470-2045(20)30600-8 |
[57] |
FRILLING A, MODLIN I M, KIDD M, et al. Recommendations for management of patients with neuroendocrine liver metastases[J]. Lancet Oncol, 2014, 15(1): e8-e21.
doi: 10.1016/S1470-2045(13)70362-0 |
[58] |
KAEMMERER D, TWRZNIK M, KULKARNI H R, et al. Prior resection of the primary tumor prolongs survival after peptide receptor radionuclide therapy of advanced neuroendocrine neoplasms[J]. Ann Surg, 2021, 274(1): e45-e53.
doi: 10.1097/SLA.0000000000003237 pmid: 33030849 |
[59] |
SPOLVERATO G, BAGANTE F, ALDRIGHETTI L, et al. Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: an international multi-institutional analysis[J]. J Surg Oncol, 2017, 116(3): 298-306.
doi: 10.1002/jso.24670 pmid: 28513896 |
[60] |
SQUIRES M H, WORTH P J, KONDA B, et al. Neoadjuvant capecitabine/temozolomide for locally advanced or metastatic pancreatic neuroendocrine tumors[J]. Pancreas, 2020, 49(3): 355-360.
doi: 10.1097/MPA.0000000000001500 |
[61] |
MURASE Y, KUDO A, AKAHOSHI K, et al. Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms[J]. Ann Gastroenterol Surg, 2021, 5(5): 692-700.
doi: 10.1002/ags3.12458 pmid: 34585054 |
[62] |
HIBI T, RELA M, EASON J D, et al. Liver transplantation for colorectal and neuroendocrine liver metastases and hepatoblastoma. Working group report from the ILTS transplant oncology consensus conference[J]. Transplantation, 2020, 104(6): 1131-1135.
doi: 10.1097/TP.0000000000003118 pmid: 32217939 |
[63] |
MORIS D, TSILIMIGRAS D I, NTANASIS-STATHOPOULOS I, et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors: a systematic review[J]. Surgery, 2017, 162(3): 525-536.
doi: 10.1016/j.surg.2017.05.006 |
[64] |
MAZZAFERRO V, SPOSITO C, COPPA J, et al. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors[J]. Am J Transplant, 2016, 16(10): 2892-2902.
doi: 10.1111/ajt.13831 pmid: 27134017 |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd